title: The efficiency of prostaglandin E2 vaginal suppositories versus intracervical prostaglandin gel for induction of labor in patients with unfavorable inducibility prospects.
abstract: Two different applications of prostaglandin E2 for induction of labor were randomly used in 113 women with an unripe cervix; 57 women were given prostaglandin suppositories each containing 2.5 mg PGE2 in a basis of Witepsol S55 (Dynamit Nobel), another 56 women were treated with intracervical gel containing 1 mg PGE2 in 5 g hydroxypropylmethyl cellulose. The treatment was repeated after 4 h if the cervix was still unripe, and the procedure was repeated the following day if the cervix was still unfavorable. Cesarean sections was performed within 48 h after the start of induction and before the second stage of labor in 8 women in the suppository group and 7 women in the intracervical gel group. Of the remaining 98 women, 73% (34/48 women) in the suppository group and 36% (18/50 women) in the cervical gel group had delivered within 24 h (p less than 0.01). After 48 h, 88% (42/48 women) in the suppository group and 74% of the women (37/50 women) in the cervical gel group had delivered (p greater than 0.05). The induction-delivery interval in the suppository group was half that found in the cervical gel group. There was no significant difference between the two groups in the use of instrumental vaginal deliveries and cesarean sections nor was there any difference with regard to fetal distress. The post-delivery condition of the newborn was similar in the two groups. No side-effects were reported in either of the two groups.
authors.affiliation: Department of Obstetrics and Gynecology, Copenhagen University Hospital, Hvidovre, Denmark.
authors.forename: J
authors.initials: J
authors.lastname: Legarth
authors.forename: E
authors.initials: E
authors.lastname: Guldbaek
authors.forename: N J
authors.initials: NJ
authors.lastname: Scher
mesh_terms: D000282:Administration, Intravaginal; D000328:Adult; D002584:Cervix Uteri / Q000187:drug effects*; D002585:Cesarean Section; D002986:Clinical Trials as Topic; D015232:Dinoprostone; D004341:Drug Evaluation; D005260:Female; D005782:Gels; D006801:Humans; D007231:Infant, Newborn; D007751:Labor, Induced / Q000379:methods*; D011247:Pregnancy; D011379:Prognosis; D011458:Prostaglandins E / Q000008:administration & dosage* / Q000494:pharmacology; D011897:Random Allocation; D013488:Suppositories; D013997:Time Factors
chemical_list: D005782:Gels; D011458:Prostaglandins E; D013488:Suppositories; D015232:Dinoprostone